Jing Zhang1, Barry Dewitt2, Evan Tang1, Daniel Breitner1, Mohammed Saqib1, Dan Li1, Rabail Siddiqui1, Nathaniel Edwards1, John Devin Peipert3,4, Ron D Hays5, Janel Hanmer6, Istvan Mucsi7. 1. Multi-Organ Transplant Program, University Health Network and University of Toronto, Toronto, Canada. 2. Department of Engineering and Public Policy, Carnegie Mellon University, Pittsburgh, Pennsylvania. 3. Department of Medical Social Sciences, Northwestern University, Chicago, Illinois. 4. Northwestern University Transplant Outcome Research Collaborative, Chicago, Illinois. 5. Department of Medicine, University of California Los Angeles, Los Angeles, California. 6. Department of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 7. Multi-Organ Transplant Program, University Health Network and University of Toronto, Toronto, Canada Istvan.mucsi@uhn.ca.
Abstract
BACKGROUND AND OBJECTIVES: A preference-based health utility score (PROPr) can be calculated using Patient-Reported Outcomes Measurement Information System domain scores. We assessed the construct validity of PROPr among patients treated with KRT (hemodialysis or kidney transplant). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a secondary analysis of data collected in multicenter, cross-sectional studies of adults treated with KRT, recruited between April 2016 to March 2020 in Toronto, Canada. All participants provided informed consent. The outcome was the PROPr score. Coadministered outcome variables included the Short-Form Six-Domain (SF-6D) and EuroQol Five-Domain Five-Level (EQ-5D-5L) scores. Socioeconomic and clinical variables included age, sex, diabetes, eGFR, serum albumin, hemoglobin, KRT, and Charlson Comorbidity Index. Construct validity was assessed through correlations between PROPr and SF-6D or EQ-5D-5L, and associations between PROPr and other exposure variables. Health-condition impact estimates (coefficients for health conditions compared with a referent category, e.g., dialysis versus kidney transplant) were calculated using multivariable linear regression. RESULTS: The mean (SD) age of the 524 participants was 57 (17) years, 58% were male, and 45% were White. Median (interquartile range) score was 0.39 (0.24-0.58) for PROPr, 0.69 (0.58-0.86) for SF-6D, and 0.85 (0.70-0.91) for EQ-5D-5L. Large correlations were observed between PROPr versus SF-6D (0.79; 95% confidence interval [95% CI], 0.76 to 0.82) and EQ-5D-5L (0.71; 95% CI, 0.66 to 0.75). Both PROPr and the other utility indices demonstrated health-condition impact in the expected direction. For example, the estimate for PROPr was -0.17 (95% CI, -0.13 to -0.21) for dialysis (versus kidney transplant), -0.05 (95% CI, -0.11 to 0.01; P=0.08) for kidney transplant recipients with an eGFR of <45 versus ≥45 ml/min per 1.73 m2, and -0.28 (95% CI, -0.22 to -0.33) for moderate/severe versus no/mild depressive symptoms. CONCLUSIONS: Our results support the validity of PROPr among patients treated with KRT.
BACKGROUND AND OBJECTIVES: A preference-based health utility score (PROPr) can be calculated using Patient-Reported Outcomes Measurement Information System domain scores. We assessed the construct validity of PROPr among patients treated with KRT (hemodialysis or kidney transplant). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a secondary analysis of data collected in multicenter, cross-sectional studies of adults treated with KRT, recruited between April 2016 to March 2020 in Toronto, Canada. All participants provided informed consent. The outcome was the PROPr score. Coadministered outcome variables included the Short-Form Six-Domain (SF-6D) and EuroQol Five-Domain Five-Level (EQ-5D-5L) scores. Socioeconomic and clinical variables included age, sex, diabetes, eGFR, serum albumin, hemoglobin, KRT, and Charlson Comorbidity Index. Construct validity was assessed through correlations between PROPr and SF-6D or EQ-5D-5L, and associations between PROPr and other exposure variables. Health-condition impact estimates (coefficients for health conditions compared with a referent category, e.g., dialysis versus kidney transplant) were calculated using multivariable linear regression. RESULTS: The mean (SD) age of the 524 participants was 57 (17) years, 58% were male, and 45% were White. Median (interquartile range) score was 0.39 (0.24-0.58) for PROPr, 0.69 (0.58-0.86) for SF-6D, and 0.85 (0.70-0.91) for EQ-5D-5L. Large correlations were observed between PROPr versus SF-6D (0.79; 95% confidence interval [95% CI], 0.76 to 0.82) and EQ-5D-5L (0.71; 95% CI, 0.66 to 0.75). Both PROPr and the other utility indices demonstrated health-condition impact in the expected direction. For example, the estimate for PROPr was -0.17 (95% CI, -0.13 to -0.21) for dialysis (versus kidney transplant), -0.05 (95% CI, -0.11 to 0.01; P=0.08) for kidney transplant recipients with an eGFR of <45 versus ≥45 ml/min per 1.73 m2, and -0.28 (95% CI, -0.22 to -0.33) for moderate/severe versus no/mild depressive symptoms. CONCLUSIONS: Our results support the validity of PROPr among patients treated with KRT.
Authors: Marta Molnar-Varga; Miklos Z Molnar; Lilla Szeifert; Agnes Z Kovacs; Andrea Kelemen; Adam Becze; Gergely Laszlo; Andras Szentkiralyi; Maria E Czira; Istvan Mucsi; Marta Novak Journal: Am J Kidney Dis Date: 2011-06-12 Impact factor: 8.860
Authors: Ryan D Nipp; Areej El-Jawahri; Samantha M Moran; Sara M D'Arpino; P Connor Johnson; Daniel E Lage; Risa L Wong; William F Pirl; Lara Traeger; Inga T Lennes; Barbara J Cashavelly; Vicki A Jackson; Joseph A Greer; David P Ryan; Ephraim P Hochberg; Jennifer S Temel Journal: Cancer Date: 2017-10-23 Impact factor: 6.860
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Joel W Neal; Mohana Roy; Kelly Bugos; Christopher Sharp; Peter S Galatin; Patricia Falconer; Eben L Rosenthal; Douglas W Blayney; Shiva Modaressi; Ashley Robinson; Kavitha Ramchandran Journal: JCO Oncol Pract Date: 2021-04-08
Authors: Janel Hanmer; David Feeny; Baruch Fischhoff; Ron D Hays; Rachel Hess; Paul A Pilkonis; Dennis A Revicki; Mark S Roberts; Joel Tsevat; Lan Yu Journal: Health Qual Life Outcomes Date: 2015-08-11 Impact factor: 3.186